Duvillier Paul
Service de Cardiologie, Centre Hospitalier de Versailles, Hôpital André Mignot, 177 rue de Versailles, 78150 Le Chesnay-Rocquencourt, France.
Ann Cardiol Angeiol (Paris). 2022 Nov;71(5):317-320. doi: 10.1016/j.ancard.2022.08.003. Epub 2022 Sep 6.
Hypertension is a very common comorbidity in patients suffering from cancer, due to common risk factors. In addition, many oncology drugs, including the new tyrosine kinase-targeting drugs, may induce hypertension or unbalance a pre-existing hypertension. Severe hypertension may lead to cardiac, renal or vascular complications and require the discontinuation or modification of anticancer treatment. It is therefore necessary to be aware of the molecules at risk. The management of hypertension in cancer is the subject of expert consensus and is based on the usual antihypertensive drugs. Adequate cardiac monitoring should be organised before, during and after treatment to allow early management and avoid possible complications. The aim is to provide optimal oncological treatment and improve short-term survival, but also to reduce the long-term cardiovascular risk of cancer survivors.
由于存在共同的风险因素，高血压在癌症患者中是一种非常常见的合并症。此外，许多肿瘤药物，包括新型酪氨酸激酶靶向药物，可能会诱发高血压或使已有的高血压病情失衡。严重高血压可能导致心脏、肾脏或血管并发症，并需要停用或调整抗癌治疗。因此，有必要了解有风险的分子。癌症患者高血压的管理是专家共识的主题，并且基于常用的抗高血压药物。在治疗前、治疗期间和治疗后应进行充分的心脏监测，以便早期管理并避免可能的并发症。目的是提供最佳的肿瘤治疗并提高短期生存率，同时降低癌症幸存者的长期心血管风险。
